Sebbagh, S., Roux, J., Dreyer, C., Neuzillet, C., de Gramont, A., Orbegoso, C., Hentic, O., Hammel, P., de Gramont, A., Raymond, E., André, T., Chibaudel, B. and Faivre, S. (2016) Efficacy of a Sequential Treatment Strategy with GEMOX-Based Followed by FOLFIRI-Based Chemotherapy in Advanced Biliary Tract Cancers. Acta Oncologica, 55, 1168-1174.
https://doi.org/10.1080/0284186X.2016.1191670

has been cited by the following article:

• TITLE: Non-Neutropenic Sepsis in Cancer Patients: The Luminal Obstruction Syndrome

  AUTHORS: Tamás Kullmann, Dóra Füzi, Tamás Pintér

  KEYWORDS: Sepsis, Biliary Sepsis, Urosepsis, Bronchogenic Sepsis, Solid Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.10 No.10, September 29, 2019

  ABSTRACT: Background: Neutropenic sepsis is a frequent complication of cytotoxic chemotherapy delivered for cancer patients. Its management is well determined by clinical guidelines. Non-neutropenic sepsis is another potential complication in cancer patients. Its management is less established in the medical literature. Materials and Methods: Three cases are presented to illustrate favourable evolution of non-neutropenic biliary-, uro- and bronchogenic-sepsis in cancer patients with poor prognosis. Results: All three patients had a survival over six months after the management of the septic complication. Two of them received subsequent systemic anticancer treatment. Conclusions: Survival benefit offered by the management of cancer-related non-neutropenic sepsis may be comparable to the benefit obtained by systemic anticancer treatments. Cost-effectiveness of sepsis management may be better than that of anticancer treatments.